These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35165715)

  • 1. Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
    Shi S; Zhang X; Yao Z; Xu M; Zhou B; Liu Q; Zhang Y; Zhou C; Zhou T; Ye J
    J Antimicrob Chemother; 2022 Apr; 77(5):1301-1305. PubMed ID: 35165715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.
    Poirel L; Kieffer N; Nordmann P
    J Antimicrob Chemother; 2016 Jan; 71(1):156-61. PubMed ID: 26416781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.
    Abbas HA; Kadry AA; Shaker GH; Goda RM
    Microb Pathog; 2019 Jul; 132():266-274. PubMed ID: 31096002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of
    Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
    Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Nelson K; Rubio-Aparicio D; Sun D; Dudley M; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482673
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
    Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on
    Yoshida I; Takata I; Fujita K; Takashima H; Sugiyama H
    Microbiol Spectr; 2022 Jun; 10(3):e0082822. PubMed ID: 35647694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii.
    Wang YC; Huang SW; Chiang MH; Lee IM; Kuo SC; Yang YS; Chiu CH; Su YS; Chen TL; Wang FD; Lee YT
    J Antimicrob Chemother; 2021 Jan; 76(2):451-459. PubMed ID: 33057603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
    Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular epidemiology of clinical isolation of carbapenem-resistant Enterobacterales and application of carbapenemase inhibitor enhancement test.
    Li H; Zhong Y; Yan Q; Liu W; Liang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 48(8):1210-1216. PubMed ID: 37875361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance.
    Ikenoue C; Matsui M; Inamine Y; Yoneoka D; Sugai M; Suzuki S;
    BMC Infect Dis; 2024 Feb; 24(1):209. PubMed ID: 38360618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant
    Kim TH; Tao X; Moya B; Jiao Y; Basso KB; Zhou J; Lang Y; Sutaria DS; Zavascki AP; Barth AL; Reeve SM; Schweizer HP; Deveson Lucas D; Boyce JD; Bonomo RA; Lee RE; Shin BS; Louie A; Drusano GL; Bulitta JB
    mBio; 2020 Feb; 11(1):. PubMed ID: 32047131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.